In rodent studies, the introduction of a gain-of-function SGK1 mutation intensified both hepatic steatosis and fibrotic responses, while CYP11B2 deficiency protected against MASLD in animals with constitutive SGK1 activation [25,40]. Here, SGK1 is linked to metabolic dysfunction-associated steatotic liver disease.